Matinas BioPharma (MTNB) Q1 2026 Annual Earnings
MTNB·Reported May 8, 2026·After market close
Diluted EPS came in at $-0.30 (+82.1% YoY), beat the $-1.32 consensus by $1.02.
Diluted EPS
$-0.30beat by $1.02
Consensus: $-1.32
Financial Snapshot
Trailing eight quarters through Q1 2026
Q1 2026 Earnings FAQ
Common questions about Matinas BioPharma's Q1 2026 earnings report.
Matinas BioPharma (MTNB) reported Q1 2026 earnings on May 8, 2026 after market close.
Matinas BioPharma reported diluted EPS of $-0.30 for Q1 2026.
EPS beat the consensus estimate of $-1.32 by $1.02.
Compared to the same quarter a year prior, diluted EPS grew 82.1% from $-1.68.
You can read the 10-K periodic report (0001493152-26-014132) directly on SEC EDGAR. The filing index links above go to sec.gov.